Cytokine and transcription factor profile of memory CD4⁺CD25⁻CD45RO⁺ T cells activated with IL-4+TGF-β.

<p><b>A)</b> Log-transformed quantities of cytokines (pg/ml) are shown. CD4⁺CD25⁻CD45RO⁺ T cells (1.0×10⁶/ml in 24 well plates) were activated with pbCD3/sCD28 in presence or absence of IL-4+TGF-β. Supernatants were collected at 96hrs post activation and IFNγ, IL-2, IL-5, IL-9, IL-10, IL-13, and IL-17 were quantified by ELISA. IL-4+TGF-β treated CD4⁺ T cells produced significantly high IL-2 and IL-9, but significantly low IFNγ, IL-13, and IL-17, as compared to CD4⁺CD25⁻CD45RO⁺ T cells not treated with IL-4+TGF-β (<i>n = 3</i>). Data is expressed as the mean±SD. <b>B)</b> Log-transformed ratios of mRNA copies to GAPDH mRNA copies for GATA3, RORC, IL-9, and Tbet are shown. CD4⁺CD25⁻CD45RO⁺ T cells (1.0×10⁶/ml in 24 well plates) were activated with pbCD3/sCD28 in presence of IL-4+TGF-β. Cells were harvested and single cell sorted. IL-9 transcripts were quantified by qt-RT-PCR. 10,000 cells comprising of total cell population (TC) was also taken and the gene expression was averaged for single cell for reference. Cells positive for IL-9 transcripts were further quantitated for GATA3, RORC, and Tbet (<i>n</i> = 3). As IL-9 is expressed in only 10% of all CD4⁺ T cells activated with pbCD3/sCD28 in presence of IL-4+TGF-β, average IL-9 mRNA copies of TC are always lower than that of a single IL-9⁺ cell. CD4⁺IL-9⁺ T cells expressed GATA3 and RORC, but not Tbet. <b>C)</b> CD4⁺CD25⁻CD45RO⁺ T cells (1.0×10⁶/ml in 24 well plates) were activated with pbCD3/sCD28 in presence of IL-4+TGF-β. Cells were surface stained for CD4 and intracellular stained for IL-9 and FOXP3. Cells were gated for CD4 and then IL-9⁺ or/and FOXP3⁺ cells were analyzed. 25% of CD4⁺IL-9⁺ T cells were also FOXP3⁺. Data are representative of seven independent experiments. <b>D)</b> CD4⁺CD25⁻CD45RO⁺ T cells (1.0×10⁶/ml in 24 well plates) were activated with pbCD3/sCD28 in presence or absence of IL-4 or TGF-β or IL-4 plus TGF-β for 96hrs and analyzed by flow cytometry for FOXP3 expression. IL-4 significantly inhibited TGF-β induced FOXP3 expression (<i>n = 3</i>). Data is expressed as the mean±SD.</p

IL-4+TGF-β in presence of pbCD3/sCD28 activation induce generation of CD4⁺IL-9⁺ T cells.

<p><b>A)</b> CD4⁺CD25⁻ T cells (1.0×10⁶/ml in 24 well plates) were activated with plate bound-anti-CD3 mAb (pbCD3)/soluble-anti-CD28 mAb (sCD28) in presence or absence of IL-4 or TGF-β or IL-4+TGF-β for 96hrs and analyzed by flow cytometry for IL-9 expression. IL-4+TGF-β in combination induced significantly higher percentage of CD4⁺ T cells positive for IL-9, as compared to IL-4, TGF-β, or neither (<i>n = 14</i>). Data is expressed as the mean±SD. <b>B)</b> CD4⁺CD25⁻ T cells, CD4⁺CD25⁻CD45RA⁺ T cells (naïve T cells), CD4⁺CD25⁻CD45RO⁺ T cells (resting memory T cells) (2.0×10⁵/ml in 96 well plates) were activated with pbCD3/sCD28 in presence of IL-4+TGF-β in a 96 well plate for 96hrs. Cells were surface stained for CD4 PerCP-Cy5.5 and intracellular stained for IL-9 PE. IL-4+TGF-β in combination induced IL-9 expression by both naïve and memory T cells, but memory T cells expressed high levels of IL-9. Data are representative of six independent experiments (six different donors).</p

CD4⁺CD25⁻ T cells activated with IL-4+TGF-β express more IL-9 than Th1, Th2, Th17, or iTregs.

<p>CD4⁺CD25⁻ T cells (1.0×10⁶/ml in 24 well plates) were activated with pbCD3/sCD28 in presence or absence of IL-4+TGF-β or Th1-, Th2-, Th17-, iTreg-polarizing condition for 96hrs. Cells were harvested, gated on CD4⁺ T cells, and were analyzed for IL-9⁺ cells by flow cytometry or were used to quantitate IL-9 transcripts by real-time PCR. Data is expressed as the mean±SD. (A) 2% of Th2 cells, 4% of iTregs, or 10% of cells treated with IL-4+TGF-β in combination were IL-9⁺, whereas Th1-, Th17-, or Th0-cells had negligible number of IL-9⁺ cells (<i>n = 7</i>); (B) Log-transformed ratios of IL-9 mRNA copies to 18S rRNA are shown. Cells treated with IL-4+TGF-β in combination had significantly higher levels of IL-9 mRNA as compared to polarized Th1-, Th2-, Th17-, iTreg-, or Th0-cells (<i>n</i> = 9).</p

IL-1β amplifies IL-4+TGF-β induced IL-9 production by memory CD4⁺CD25⁻CD45RO⁺ T cells.

<p>Resting memory CD4⁺CD25⁻CD45RO⁺ T cells (2.0×10⁵/ml in 96 well plates) activated with pbCD3/sCD28 alone or with IL-4+TGF-β, in the presence or absence of IL-1β, IL-2, IL-6, IL-12, and IL-21 for 96hrs and supernatants were collected. Influence of IL-1β, IL-2, IL-6, IL-12, and IL-21 on IL-9 production of IL-4+TGF-β treated CD4⁺CD25⁻CD45RO⁺ T cells was examined. IL-1β, IL-12 or IL-21 significantly elevated IL-4+TGF-β induced IL-9 production, but IL-1β had significantly higher influence compared to IL-12 or IL-21 (<i>n = 3</i>). Data is expressed as the mean±SD.</p

Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

Individuals with rare kidney diseases account for 5-10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure.People aged 0-96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan-Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m2 or more to first eGFR of less than 30 mL/min per 1·73 m2 (the therapeutic trial window).Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9-16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p Background Methods Findings Interpretation Funding</p